2020 Postcard from Palm Springs
Highlights from the 2020 CHDI HD Therapeutics Conference are now here! This year’s Postcard covers HTT-lowering therapeutics, including an
Read more
Navigator Research Program
THE 2023 COMPETITION IS CLOSED
Navigator Research Program Overview
Our mission at HSC is to improve the quality of life for those affected by Huntington disease. One of the ways that we address our mission is by investing in promising research.
The Navigator Research Program has been providing funding to support HD researchers since 2003 with awards up to $75,000/year for 1-2 years.
Goals of the Navigator Research Program include:
- Funding for Canadian scientific research of direct and immediate relevance to Huntington Disease
- To provide a platform for the future recruitment of outstanding investigators to HD research
- To facilitate research collaboration nationally and internationally
- To support research which is relevant to other neurodegenerative disorders as well as HD
Click here for the Navigator Research Program – Terms of Reference
Click here for the Navigator Research Program – Application for Funding
Click here for the 2023 Research Competition Letter of Intent
2023 RECIPIENT – CLICK HERE FOR PAST RECIPIENTS
Dr. Michael Hayden MBChB, PhD – University of British Columbia
Michael Hayden is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. He is also a Canada Research Chair in Human Genetics and Molecular Medicine. Additionally, Dr. Hayden is the co-founder of five biotechnology companies, including NeuroVir, Xenon, Aspreva, 89bio and Prilenia. He serves as a Board Member for different public and private biotechnology companies. Dr. Hayden is the author of ~900 peer-reviewed publications and invited submissions and the recipient of numerous prestigious honours and awards. He was inducted into the Canadian Medical Hall of Fame in 2017 and was awarded the Order of Canada in 2010 and Order of British Columbia in 2009.
Dr. Chris Kay PhD – University of British Columbia
Chris Kay is a Research Associate in the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. He completed his PhD in Medical Genetics under the supervision of Dr. Michael Hayden in 2017 and now works to identify and develop novel therapeutic targets through discovery and preclinical stages, using high-throughput candidate evaluation methods from genetics, molecular biology and cell biology. Dr. Kay has published over two dozen studies on human disease haplotypes and gene silencing strategies, with a focus on inherited neurological disease.
